These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32463773)

  • 1. Introduction: Pharmacy Reimbursement.
    Greenwood BC
    J Manag Care Spec Pharm; 2020 Jun; 26(6):702. PubMed ID: 32463773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of the Pharmacy Benefit Manager/Community Pharmacy Relationship: An Opportunity for Success.
    Taddei-Allen P
    J Manag Care Spec Pharm; 2020 Jun; 26(6):708-710. PubMed ID: 32463767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To Reform Pharmacy Reimbursement Begin with the Basics.
    Rupp MT
    J Manag Care Spec Pharm; 2020 Jun; 26(6):713-715. PubMed ID: 32463772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication review and patient counselling at discharge from the hospital by community pharmacists.
    Hugtenburg JG; Borgsteede SD; Beckeringh JJ
    Pharm World Sci; 2009 Dec; 31(6):630-7. PubMed ID: 19649720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the effects of Medicare Part D from key stakeholders' perspectives: Important progress, but abundant research opportunities remain.
    Urmie JM; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):85-9. PubMed ID: 20511107
    [No Abstract]   [Full Text] [Related]  

  • 6. Can a pharmacist reduce annual costs for Medicare Part D enrollees?
    Alston G; Hanrahan C
    Consult Pharm; 2011 Mar; 26(3):182-9. PubMed ID: 21402518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1206-1213. PubMed ID: 32780612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Medicare Part D on independent and chain community pharmacies in rural Illinois--A qualitative study.
    Bono JD; Crawford SY
    Res Social Adm Pharm; 2010 Jun; 6(2):110-20. PubMed ID: 20511110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program.
    Jódar-Sánchez F; Malet-Larrea A; Martín JJ; García-Mochón L; López Del Amo MP; Martínez-Martínez F; Gastelurrutia-Garralda MA; García-Cárdenas V; Sabater-Hernández D; Sáez-Benito L; Benrimoj SI
    Pharmacoeconomics; 2015 Jun; 33(6):599-610. PubMed ID: 25774017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capitation reimbursement for pharmacy services: a dissenting view.
    Gosselin RA
    Med Mark Media; 1980 Oct; 15(10):51-6. PubMed ID: 10249122
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.
    Roebuck MC; Liberman JN
    Health Serv Res; 2009 Jun; 44(3):988-1009. PubMed ID: 19187183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of Medicare Part D for community pharmacies.
    Stone D
    J Manag Care Pharm; 2009 Mar; 15(2):171-2. PubMed ID: 19236134
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Employer and Plan Sponsor Views on Pharmacy Reimbursement.
    Stull M; Gupton C
    J Manag Care Spec Pharm; 2020 Jun; 26(6):710-712. PubMed ID: 32463776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges for Managed Care from 340B Contract Pharmacies.
    Fein AJ
    J Manag Care Spec Pharm; 2016 Mar; 22(3):197-203. PubMed ID: 27003548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.
    Shah ED; Chang L; Lembo A; Staller K; Curley MA; Chey WD
    Dig Dis Sci; 2021 Dec; 66(12):4140-4148. PubMed ID: 33433804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.